Innovent Biologics, Inc.
HKSE: 1801.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- De-Chao Yu
- Employees
- 5,659
- Headquarters
- Suzhou, China
- IPO year
- 2018
- Market cap
- HK$156.1B
- Website
- https://www.innoventbio.com
Loading 1801…
Loading profile data…Frequently asked questions about 1801
What does Innovent Biologics, Inc. (1801.HK) do?
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody f...
Where does 1801.HK trade?
Innovent Biologics, Inc. (1801.HK) trades on the Hong Kong Stock Exchange.
What sector is 1801.HK in?
Innovent Biologics, Inc. (1801.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Innovent Biologics, Inc.?
De-Chao Yu is the chief executive officer of Innovent Biologics, Inc. (1801.HK).
Where is Innovent Biologics, Inc. headquartered?
Innovent Biologics, Inc. is headquartered in China.
Does 1801.HK pay a dividend?
Innovent Biologics, Inc. (1801.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 1801.HK go public?
Innovent Biologics, Inc. (1801.HK) completed its initial public offering in 2018.